Correlation Between Enlivex Therapeutics and ALK-Abelló A/S

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Enlivex Therapeutics and ALK-Abelló A/S at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enlivex Therapeutics and ALK-Abelló A/S into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enlivex Therapeutics and ALK Abell AS, you can compare the effects of market volatilities on Enlivex Therapeutics and ALK-Abelló A/S and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enlivex Therapeutics with a short position of ALK-Abelló A/S. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enlivex Therapeutics and ALK-Abelló A/S.

Diversification Opportunities for Enlivex Therapeutics and ALK-Abelló A/S

0.05
  Correlation Coefficient

Significant diversification

The 3 months correlation between Enlivex and ALK-Abelló is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Enlivex Therapeutics and ALK Abell AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ALK-Abelló A/S and Enlivex Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enlivex Therapeutics are associated (or correlated) with ALK-Abelló A/S. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ALK-Abelló A/S has no effect on the direction of Enlivex Therapeutics i.e., Enlivex Therapeutics and ALK-Abelló A/S go up and down completely randomly.

Pair Corralation between Enlivex Therapeutics and ALK-Abelló A/S

Given the investment horizon of 90 days Enlivex Therapeutics is expected to under-perform the ALK-Abelló A/S. In addition to that, Enlivex Therapeutics is 1.04 times more volatile than ALK Abell AS. It trades about -0.27 of its total potential returns per unit of risk. ALK Abell AS is currently generating about -0.22 per unit of volatility. If you would invest  2,235  in ALK Abell AS on November 6, 2024 and sell it today you would lose (205.00) from holding ALK Abell AS or give up 9.17% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy95.0%
ValuesDaily Returns

Enlivex Therapeutics  vs.  ALK Abell AS

 Performance 
       Timeline  
Enlivex Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enlivex Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.
ALK-Abelló A/S 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ALK Abell AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's essential indicators remain nearly stable which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Enlivex Therapeutics and ALK-Abelló A/S Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Enlivex Therapeutics and ALK-Abelló A/S

The main advantage of trading using opposite Enlivex Therapeutics and ALK-Abelló A/S positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enlivex Therapeutics position performs unexpectedly, ALK-Abelló A/S can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ALK-Abelló A/S will offset losses from the drop in ALK-Abelló A/S's long position.
The idea behind Enlivex Therapeutics and ALK Abell AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Valuation
Check real value of public entities based on technical and fundamental data
CEOs Directory
Screen CEOs from public companies around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals